Ikarian Capital, LLC Achilles Therapeutics PLC Transaction History
Ikarian Capital, LLC
- $754 Million
- Q1 2024
A detailed history of Ikarian Capital, LLC transactions in Achilles Therapeutics PLC stock. As of the latest transaction made, Ikarian Capital, LLC holds 1,443,181 shares of ACHL stock, worth $1.33 Million. This represents 0.24% of its overall portfolio holdings.
Number of Shares
1,443,181
Previous 1,443,181
-0.0%
Holding current value
$1.33 Million
Previous $1.8 Million
-0.0%
% of portfolio
0.24%
Previous 0.24%
Shares
1 transactions
Others Institutions Holding ACHL
# of Institutions
34Shares Held
23.5MCall Options Held
0Put Options Held
0-
Syncona Portfolio LTD Guernsey, Channel Islands, X011.1MShares$10.2 Million9.24% of portfolio
-
Fcpm Iii Services B.V. Naarden, P72.39MShares$2.2 Million0.42% of portfolio
-
Redmile Group, LLC San Francisco, CA1.61MShares$1.48 Million0.08% of portfolio
-
Vestal Point Capital, LP New York, NY1.5MShares$1.38 Million0.16% of portfolio
-
Stem Point Capital LP New York, NY1.39MShares$1.27 Million0.46% of portfolio
About Achilles Therapeutics plc
- Ticker ACHL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,774,000
- Market Cap $37.5M
- Description
- Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in ...